Corvus Pharmaceuticals Inc(CRVS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:46 PM ET (Korea 10/29 05:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.62 | Insider Own | 22.97% | Shs Outstand | 84.1M | Perf Week | 4.68% |
| Market Cap | 0.88B | Forward P/E | - | EPS next Y | -24.31% | Insider Trans | 0.15% | Shs Float | 64.8M | Perf Month | -10.54% |
| Enterprise Value | 0.67B | PEG | - | EPS next Q | -0.19 | Inst Own | 65.85% | Short Float | 27.73% | Perf Quarter | -20.24% |
| Income | -0.05B | P/S | - | EPS this Y | -293.49% | Inst Trans | 1.22% | Short Ratio | 18.04 | Perf Half Y | -27.05% |
| Sales | 0.00B | P/B | 3.93 | EPS next 5Y | - | ROA | -32.93% | Short Interest | 17.97M | Perf YTD | 36.62% |
| Book/sh | 2.68 | P/C | 4.11 | EPS past 3/5Y | 15.4% -21.44% | ROE | -35.43% | 52W High | -60.96% ($26.95) | Perf Year | 38.6% |
| Cash/sh | 2.56 | P/FCF | - | Sales past 3/5Y | - | ROIC | -23.99% | 52W Low | 64.63% ($6.39) | Perf 3Y | 839.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 8.13% | Gross Margin | - | Volatility(W/M) | 5.13% 5.74% | Perf 5Y | 127.71% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.6 | Perf 10Y | -22.82% |
| Dividend Ex-Date | - | Quick Ratio | 16.16 | EPS Q/Q | -89.11% | Profit Margin | - | RSI (14) | 45.3 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.16 | Sales Q/Q | - | SMA20 | 2.58% ($10.26) | Beta | 1.54 | Target Price | $33.14 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -13.28% ($12.13) | Rel Volume | 0.92 | Prev Close | $10.54 |
| Employees | 37 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -19.42% - | SMA200 | -26.99% ($14.41) | Avg Volume(3M) | 1.00M | Price | $10.52 |
| IPO | 2016/3/23 | Option/Short | Yes/Yes | Trades | 10993 | Volume | 911,734 | Change | -0.19% |
🧬 Corvus Pharmaceuticals (Corvus, CRVS) is a US clinical-stage biotech company developing oncology and immune disease therapeutics centered on a differentiated immunomodulatory mechanism known as ITK inhibition. Its lead candidate, soquelitinib, is an oral small-molecule selective ITK inhibitor being clinically developed primarily for atopic dermatitis and T-cell lymphoma. The company has a typical biotech structure with high single-asset concentration.
Over the past 1 year, on the lower side
61% below its 1-year high.
Traded about as much as usual. That is 92% of its average volume.
CRVS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -293.5% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +127.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
27.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #172 of 594 in the industry
Based on market cap of $885M.
OBX#170 Obsidian Therapeutics Inc $901M PER 0.1 
DNA#171 Ginkgo Bioworks Holdings Inc $897M PER - CRVS#172 Corvus Pharmaceuticals Inc $885M PER - 
IVA#173 Inventiva ADR $883M PER - 
PHAR#174 Pharming Group NV ADR $868M PER 38.9 
FAQ
What kind of company is CRVS?
CRVS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRVS?
The market cap of CRVS is approximately $885M, ranking 2,685 within its sector.
What is the 52-week high and low for CRVS?
CRVS has recorded a 52-week high of $26.95 and a low of $6.39.
